Weekly Docetaxel Plus Cisplatin as the First-line Therapy for Nasopharyngeal Cancer

Samsung Medical Center51 enrolled

Overview

The investigators will evaluate weekly docetaxel plus 3-weekly cisplatin regimen as the first-line therapy for recurrent of metastatic nasophayngeal cancer

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Nasopharyngeal Cancer

Interventions

Docetaxel, CisplatinDRUG

Docetaxel 35mg/m2 D1 \& D8 Cisplatin 70mg/m2 D1

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * histologically confirmed nasopharyngeal cancer * chemotherapy or radiotherapy naive (but, including patients completed 6 months before the enrollment) * ECOG 0-1 * at least one measurable lesion Exclusion Criteria: * other cancer * pregnat * docetaxel hypersentitivity history * severe heart or pulmonary disease

Locations (1)

Samsung Medical Center

Seoul, South Korea

RECRUITING

Outcomes

Primary Outcomes

objective response rate

Time frame: 6 months after the enrollment of the last patients

Secondary Outcomes

number of patients with adverse events

Time frame: simultaneously when the analysis of primary endpoint

Central Contacts

Myung-Ju Ahn, Pf

CONTACT

82-2-3410-3459 silkahn@skku.edu

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.